Program
Tadalafil
Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.
Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Drug pageTadalafil: every studyMany companies study it; this page follows only the 59 they lead. All 193 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 490 open or running | phase 4since May 31, 2006 | Dec 16, 2002 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Pfizerits history only | 20 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Futura Medical Developmentsits history only | 10 open or running | phase 3since Jul 26, 2021 | Jul 26, 2021 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Sep 4, 2014 | Sep 4, 2014 | none ahead |
| lidia-larran-agaits history only | 10 open or running | phase 3since May 6, 2020 | May 6, 2020 | none ahead |
| Sanofi | 10 open or running | phase 3since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Seattle Gummyits history only | 11 open or running | phase 1since Feb 17, 2021 | Feb 17, 2021 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, Nippon Shinyaku and ICOS.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2025First study: phase 3 study in Erectile DysfunctionFirst studyNCT06805513 · 2,212 enrolled · United States
TargetBeta
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule
Other programs on PDE5A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sildenafilrule | Viatris | phase 4 | 74 |
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06805513Erectile Dysfunction · United States | 3 | Completed | Mar 2, 2026 | 2,212 |
How it is read
Names in the registry
- “tadalafil”, 45 entries
- “Tadalafil”, 25 entries
- “Tadalafil 20 mg”, 2 entries
- “Cialis Tab. 5mg”, 2 entries
- “Tadalafil 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Erectile Dysfunction, 32 studies
- Prostatic Hyperplasia, 18 studies
- Hypertension, Pulmonary, 4 studies
- Pulmonary Arterial Hypertension, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.